Abstract
Alpha-methyl-para-tyrosine (AMPT) temporarily inhibits tyrosine hydroxylase, the rate limiting step in the dopamine biosynthesis cascade. AMPT has been approved for clinical use in phaeochromocytoma in 1979. Recently however, AMPT has been increasingly employed as a pharmacological challenge in acute dopamine depletion studies including neuroimaging studies. The use of this exciting challenge technique allows us to increase our understanding of dopaminergic neurotransmission in the brain. In addition, there have been clinical reports that AMPT may be useful to treat movement disorders like dystonia, dyskinesia and Huntingtons chorea, psychiatric disorders like mania, psychosis, obsessive compulsive disorder and substance abuse as well as behavioral problems in 22q11 deletion syndrome. In this review we will discuss the effects of AMPT in challenge studies that have been reported in humans. Furthermore we will review all studies reporting therapeutic effects of AMPT in neuropsychiatric disorders and adverse effects associated with AMPT use reported in both challenge and therapeutic research.
Keywords: Alpha-methyl-para-tyrosine, AMPT, dopamine, depletion, challenge, treatment, catecholamine
Central Nervous System Agents in Medicinal Chemistry
Title: Challenge and Therapeutic Studies Using Alpha-Methyl-para-Tyrosine (AMPT) in Neuropsychiatric Disorders: A Review
Volume: 8 Issue: 4
Author(s): Oswald J.N. Bloemen, M. B. de Koning, E. Boot, J. Booij and T.A. M.J. van Amelsvoort
Affiliation:
Keywords: Alpha-methyl-para-tyrosine, AMPT, dopamine, depletion, challenge, treatment, catecholamine
Abstract: Alpha-methyl-para-tyrosine (AMPT) temporarily inhibits tyrosine hydroxylase, the rate limiting step in the dopamine biosynthesis cascade. AMPT has been approved for clinical use in phaeochromocytoma in 1979. Recently however, AMPT has been increasingly employed as a pharmacological challenge in acute dopamine depletion studies including neuroimaging studies. The use of this exciting challenge technique allows us to increase our understanding of dopaminergic neurotransmission in the brain. In addition, there have been clinical reports that AMPT may be useful to treat movement disorders like dystonia, dyskinesia and Huntingtons chorea, psychiatric disorders like mania, psychosis, obsessive compulsive disorder and substance abuse as well as behavioral problems in 22q11 deletion syndrome. In this review we will discuss the effects of AMPT in challenge studies that have been reported in humans. Furthermore we will review all studies reporting therapeutic effects of AMPT in neuropsychiatric disorders and adverse effects associated with AMPT use reported in both challenge and therapeutic research.
Export Options
About this article
Cite this article as:
Bloemen J.N. Oswald, de Koning B. M., Boot E., Booij J. and van Amelsvoort M.J. T.A., Challenge and Therapeutic Studies Using Alpha-Methyl-para-Tyrosine (AMPT) in Neuropsychiatric Disorders: A Review, Central Nervous System Agents in Medicinal Chemistry 2008; 8 (4) . https://dx.doi.org/10.2174/187152408786848102
DOI https://dx.doi.org/10.2174/187152408786848102 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Cathepsin K in Normal Joints and in the Development of Arthritis
Current Drug Targets Genomic and Pharmacogenomic Biomarkers of Parkinson’s Disease
Current Drug Metabolism Evaluation of Pregabalin Therapy in Peripheral Neuropathy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Structural Characterization of Alpha-methylacyl-CoA Racemase: Comparative Structural Modeling, Molecular Docking and Dynamic Simulations Studies
Current Cancer Drug Targets From Laptop to Benchtop to Bedside: Structure-based Drug Design on Protein Targets
Current Pharmaceutical Design Effects of Gastrodia Elata Bl on Phencyclidine-Induced Schizophrenia-Like Psychosis in Mice
Current Neuropharmacology Phosphodiesterase Inhibitors as Potential Cognition Enhancing Agents
Current Topics in Medicinal Chemistry Recent Advances on the Possible Neuroprotective Activities of Epstein- Barr Virus Oncogene BARF1 Protein in Chronic Inflammatory Disorders of Central Nervous System
Current Neuropharmacology Electrochemical Behavior of Porous Carbon Nanofibers Developed from Polyacrylonitrile/ Graphene Solutions Containing Zinc Chloride
Current Organic Chemistry Do mtDNA Mutations Participate in the Pathogenesis of Sporadic Parkinsons Disease?
Current Genomics Perspective of Cyclin-dependent kinase 9 (CDK9) as a Drug Target
Current Pharmaceutical Design Subthreshold Diode Micropulse Laser Photocoagulation (SDM) as Invisible Retinal Phototherapy for Diabetic Macular Edema: A Review
Current Diabetes Reviews Molecule of the Month
Current Topics in Medicinal Chemistry Impact of HLA Haplotype on the Response to Antipsychotic Treatment of Schizophrenia
Current Pharmacogenomics Memories are Made of This (Perhaps): A Review of Serotonin 5-HT6 Receptor Ligands and Their Biological Functions
Current Topics in Medicinal Chemistry Prevalence of Comorbid Anxiety Disorders in Schizophrenia Spectrum Disorders: A Literature Review
Current Psychiatry Reviews Crystallographic Cryoenzymology and the Legacy of Tony Fink
Current Protein & Peptide Science Mechanism-Based Inactivators as Probes of Cytochrome P450 Structure and Function
Current Drug Metabolism Molecular Modelling and QSAR in the Discovery of HIV-1 Integrase Inhibitors
Current Computer-Aided Drug Design Formulation Studies on Novel Self-Solidifying Self-Nanoemulsifying Drug Delivery Systems of Nebivolol Hydrochloride
Pharmaceutical Nanotechnology